Maissaa Janbain is an Oncology physician affiliated with Tulane University. OpenAlex indexes 58 publications with 381 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1430 Tulane Ave
Sl#78
New Orleans, LA 701122632
Telephone
504-988-5482Registry record last updated 19 Apr 2017.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202545 payments$128,905openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202522 payments$36,218openpaymentsdata.cms.gov ↗
- CSL BehringProgram year202518 payments$18,885openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Antifibrinolytic Agent100%Tranexamic Acid100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study
Journal of Thrombosis and Haemostasis
2025 - Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study
Blood Vessels Thrombosis & Hemostasis
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Erik Castle, MD
Tulane University
John Schieffelin, MD
Tulane University
Thierry Lejemtel, MD
Tulane University
Robert Hendel, MD
Tulane University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”